Be part of the knowledge.™

Rare and Orphan Diseases

389

LikeLikedUnlike

Episodes 151-165 of 253

Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
Project Oncology®
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
ATTR-CM Screening: How Economic Factors Can Impact Care
Heart Matters
ATTR-CM Screening: How Economic Factors Can Impact Care
- Kibum Kim, PhD
  Peer
Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
NeuroFrontiers
Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
- Nancy Kuntz, MD
  Peer
Duchenne Muscular Dystrophy Management: Analyzing Current Approaches
NeuroFrontiers
Duchenne Muscular Dystrophy Management: Analyzing Current Approaches
- Nancy Kuntz, MD
  Peer
Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
Project Oncology®
Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
- Shaji K. Kumar, MD
  Peer
Generalized Myasthenia Gravis Management: Evaluating Long-Term Effects
NeuroFrontiers
Generalized Myasthenia Gravis Management: Evaluating Long-Term Effects
- Maxwell H. Levy, MD
  Peer
advertisement
The Impact of a Plant-Based Diet on Multiple Myeloma Prevention and Progression
Project Oncology®
The Impact of a Plant-Based Diet on Multiple Myeloma Prevention and Progression
- Urvi A. Shah, MD, MS
  Peer
Patient Case: ATTRwt-CM Discovered Decades After Heart Transplant
Heart Matters
Patient Case: ATTRwt-CM Discovered Decades After Heart Transplant
- Lily Stern, MD
  Peer
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
Project Oncology®
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
NeuroFrontiers
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
NeuroFrontiers
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
- Maxwell H. Levy, MD
  Peer
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Spotlight On ATTR-CM
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
advertisement
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
Spotlight On ATTR-CM
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Project Oncology®
Exercise in Multiple Myeloma: Balancing Benefits and Safety
- Jens Hillengass, MD, PhD
  Peer
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
- Gil I. Wolfe MD, FAAN
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended